Tempest Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.75 Insider Own3.25% Shs Outstand13.64M Perf Week0.00%
Market Cap17.59M Forward P/E- EPS next Y-2.84 Insider Trans0.00% Shs Float10.18M Perf Month-20.28%
Income-34.40M PEG- EPS next Q-0.76 Inst Own71.30% Short Float / Ratio0.16% / 0.91 Perf Quarter-21.40%
Sales- P/S- EPS this Y74.20% Inst Trans-0.43% Short Interest0.02M Perf Half Y-45.83%
Book/sh1.96 P/B0.86 EPS next Y12.60% ROA-50.10% Target Price17.67 Perf Year-79.64%
Cash/sh- P/C- EPS next 5Y- ROE-108.10% 52W Range1.42 - 9.14 Perf YTD-67.99%
Dividend- P/FCF- EPS past 5Y58.10% ROI- 52W High-81.51% Beta0.51
Dividend %- Quick Ratio2.50 Sales past 5Y- Gross Margin- 52W Low19.01% ATR0.14
Employees17 Current Ratio2.50 Sales Q/Q- Oper. Margin- RSI (14)49.19 Volatility7.66% 8.44%
OptionableNo Debt/Eq0.57 EPS Q/Q45.70% Profit Margin- Rel Volume0.41 Prev Close1.53
ShortableYes LT Debt/Eq0.44 Earnings- Payout- Avg Volume17.56K Price1.69
Recom1.50 SMA200.68% SMA50-1.88% SMA200-32.24% Volume7,171 Change10.46%
Nov-22-22 04:05PM
Nov-10-22 09:00AM
Nov-08-22 08:00AM
Nov-02-22 08:00AM
Oct-06-22 08:00AM
08:00AM Loading…
Sep-07-22 08:00AM
Aug-15-22 08:00AM
Jul-07-22 08:00AM
Jun-09-22 08:00AM
Jun-06-22 04:05PM
May-26-22 04:57PM
May-13-22 08:00AM
Apr-27-22 10:01AM
Apr-08-22 01:00PM
04:00PM Loading…
Mar-29-22 04:00PM
Mar-10-22 08:00AM
Mar-08-22 04:30PM
Feb-09-22 08:00AM
Nov-18-21 08:00AM
Nov-12-21 07:00AM
Nov-10-21 04:05PM
Nov-09-21 08:00AM
Nov-08-21 08:00AM
Oct-01-21 08:00AM
Sep-20-21 08:00AM
Sep-13-21 08:00AM
Sep-09-21 04:01PM
Aug-12-21 04:01PM
Aug-09-21 08:00AM
08:00AM Loading…
Jul-09-21 08:00AM
Jul-01-21 04:00PM
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Woiwode ThomasDirectorApr 29Buy2.362,118,6445,000,0002,118,644May 03 05:49 PM
Dubensky Thomas W.PresidentJan 07Buy4.782,0009,560113,343Jan 11 06:36 PM
Whiting SamuelChief Medical OfficerJan 06Buy4.801,7008,1681,901Jan 10 06:37 PM